General Information of Drug Transporter (DT)
DT ID	DTD0012 Transporter Info
Gene Name	ABCC3
Protein Name	Multidrug resistance-associated protein 3
Gene ID	8714
UniProt ID	O15438
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1051640
Site of GPD	chr17:50691125 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1040/521 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:         14 Drugs in Total
Cisplatin	Drug Info	Neoplasm	Correlated with the increased ototoxicity risk in patients (compare with Allele A); Irrelevant to the ototoxicity risk in patients (compare with allele A)		[ 1], [ 2], [ 3]
Cisplatin	Drug Info	Testicular Neoplasm	Irrelevant to the likelihood of ototoxicity in patients (compare with allele A)		[ 4]
Cisplatin	N.A.	Ototoxicity	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.		[ 4]
Cisplatin	N.A.	Ototoxicity	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.		[ 1]
Cisplatin	N.A.	Ototoxicity	Allele G is not associated with risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele A.		[ 3]
Cisplatin	N.A.	Ototoxicity	Allele G is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.		[ 5]
Cisplatin	N.A.	Drug Toxicity	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.		[ 1]
Cisplatin	N.A.	Neoplasms	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.		[ 1]
Cisplatin	N.A.	Drug Toxicity	Allele G is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.		[ 5]
Cisplatin	N.A.	Neoplasms	Allele G is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.		[ 5]
Cisplatin	N.A.	Drug Toxicity	Allele G is not associated with risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele A.		[ 3]
Cisplatin	N.A.	Neoplasms	Allele G is not associated with risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele A.		[ 3]
Cisplatin	N.A.	Drug Toxicity	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.		[ 4]
Cisplatin	N.A.	Neoplasms	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.		[ 4]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Drug Toxicity	Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Neoplasms	Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Ototoxicity	Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Drug Toxicity	Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Neoplasms	Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Ototoxicity	Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Drug Toxicity	Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Neoplasms	Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Cisplatin	N.A.	Ototoxicity	Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.		[ 1]
Genetic Polymorphism	rs4148416
Site of GPD	chr17:50676062 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1370/686 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         16 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with allele C)		[ 6]
Vincristine	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with allele C)		[ 6]
Cisplatin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with allele C)		[ 6]
Doxorubicin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with allele C)		[ 6]
Cyclophosphamide	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with allele C)		[ 6]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 7]
Cisplatin	N.A.	Toxic Liver Disease	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Cyclophosphamide	N.A.	Toxic Liver Disease	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Doxorubicin	N.A.	Toxic Liver Disease	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Methotrexate	N.A.	Toxic Liver Disease	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Vincristine	N.A.	Toxic Liver Disease	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Cisplatin	N.A.	Osteosarcoma	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Cyclophosphamide	N.A.	Osteosarcoma	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Doxorubicin	N.A.	Osteosarcoma	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Methotrexate	N.A.	Osteosarcoma	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Vincristine	N.A.	Osteosarcoma	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.		[ 6]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 8]
Cisplatin	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Doxorubicin	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Methotrexate	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Vincristine	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Cisplatin	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Doxorubicin	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Methotrexate	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Vincristine	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Cisplatin	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Doxorubicin	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Methotrexate	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Vincristine	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		[ 6]
Genetic Polymorphism	rs4793665
Site of GPD	chr17:50634726 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.3313/1659 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Morphine	Drug Info	Pain	Correlated with the increased drug metabolism in patients (compare with Genotypes CT + TT)		[ 9]
Morphine	N.A.	Overall Survival	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.		[ 9]
Morphine-3-glucuronide	N.A.	Thrombocytopenia	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.		[ 10]
Morphine-6-glucuronide	N.A.	Thrombocytopenia	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.		[ 10]
Morphine	N.A.	Pain	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.		[ 9]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Cisplatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes CC + CT.		[ 11]
Doxorubicin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes CC + CT.		[ 11]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes CC + CT.		[ 11]
Etoposide	N.A.	Overall Survival	Genotype TT is associated with decreased overall survival when treated with etoposide and Platinum compounds in people with Small cell carcinoma as compared to genotypes CC + CT.		[ 12]
Platinum Compounds	N.A.	Overall Survival	Genotype TT is associated with decreased overall survival when treated with etoposide and Platinum compounds in people with Small cell carcinoma as compared to genotypes CC + CT.		[ 12]
Morphine	N.A.	Pain	Patients with the TT genotype may have decreased metabolism of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.		[ 9]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Clopidogrel	N.A.	Toxic Liver Disease	Genotypes CC + CT are not associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing percutaneous coronary intervention when treated with clopidogrel as compared to genotype TT.		[ 13]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele T is associated with decreased clearance of morphine in children as compared to allele C.		[ 14]
Morphine	N.A.	Pain	Allele T is associated with decreased clearance of morphine in children as compared to allele C.		[ 14]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Toxic Liver Disease	Allele C is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to allele T.		[ 15]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Pain	Patients with the CT genotype may have decreased metabolism of morphine as compared to patients with the CC genotype, but increased metabolism of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.		[ 9]
Genetic Polymorphism	rs9895420
Site of GPD	chr17:50634677 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	A=0.1276/639 (Global)
Genotypes AA + AT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased likelihood of thrombocytopenia in patients (compare with Genotype TT); Correlated with the increased drug plasma levels in patients (compare with Genotype TT); Correlated with the increased relapse in the central nervous system risk in patients (compare with Genotype TT)		[ 16]
Methotrexate	N.A.	Overall Survival	Genotypes AA + AT are associated with increased plasma levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 16]
Methotrexate	N.A.	Thrombocytopenia	Genotypes AA + AT are associated with decreased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 16]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 16]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 16]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the AT genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 16]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the TT genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 16]
Genetic Polymorphism	rs4148405
Site of GPD	chr17:50636207 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>G
Minor Allele Frequency	T=0.7280/1440 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Busulfan	N.A.	Toxic Liver Disease	Allele G is associated with decreased Disease-Free Survival when treated with busulfan, cytarabine and etoposide in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 17]
Cytarabine	N.A.	Toxic Liver Disease	Allele G is associated with decreased Disease-Free Survival when treated with busulfan, cytarabine and etoposide in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 17]
Etoposide	N.A.	Toxic Liver Disease	Allele G is associated with decreased Disease-Free Survival when treated with busulfan, cytarabine and etoposide in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 17]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele G is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele T.		[ 18]
Genetic Polymorphism	rs4148412
Site of GPD	chr17:50656454 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3230/639 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele T is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele C.		[ 10]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine-3-glucuronide	N.A.	Thrombocytopenia	Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT.		[ 10]
Genetic Polymorphism	rs739923
Site of GPD	chr17:50658413 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6870/1359 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele A.		[ 10]
Genetic Polymorphism	rs11079921
Site of GPD	chr17:50675018 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.9320/1844 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fentanyl	N.A.	Thrombocytopenia	Allele C is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele T.		[ 19]
Genetic Polymorphism	rs8077268
Site of GPD	chr17:50676161 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9460/1872 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fentanyl	N.A.	Thrombocytopenia	Allele T is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele C.		[ 19]
Genetic Polymorphism	rs886493
Site of GPD	chr17:50667251 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.4670/924 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele G is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele T.		[ 18]
Morphine	N.A.	Hypoventilation	Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele T.		[ 10]
Genetic Polymorphism	rs28470592
Site of GPD	chr17:50650003 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.5950/1177 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 18]
Genetic Polymorphism	rs4148415
Site of GPD	chr17:50675239 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.6820/1349 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 18]
Genetic Polymorphism	rs1978153
Site of GPD	chr17:50660500 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5620/1112 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele C is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele G.		[ 10]
Genetic Polymorphism	rs733392
Site of GPD	chr17:50659042 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7030/1391 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele A.		[ 10]
Genetic Polymorphism	rs7216383
Site of GPD	chr17:50662182 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.6660/1318 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Hypoventilation	Allele T is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele C.		[ 10]
References
1	Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243-51.
2	Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2014 Sep;96(3):296-8.
3	Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin. Pharmacogenomics J. 2017 Dec;17(6):515-520.
4	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562.
5	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics J. 2020 Apr;20(2):294-305.
6	Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6(10):e26091.
7	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
8	Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma. Xenobiotica. 2022 Mar;52(3):265-273.
9	ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
10	ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. Pharmacogenomics J. 2017 Mar;17(2):162-169.
11	Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024 Dec 12;16(12).
12	ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics. 2024 Aug 25;16(9).
13	Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2013 Aug;40(8):504-9.
14	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. J Clin Pharmacol. 2020 Aug;60(8):992-998.
15	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Feb 07;8(6):9388-9398.
16	Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2012 Oct;12(5):386-94.
17	Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013 Jun;58(6):353-61.
18	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
19	Fentanyl dosage for preterm infants suggested by a pharmacokinetic, -dynamic, and -genetic model. Pediatr Res. 2025 Jan;97(1):239-245.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.